Asia Pacific prostate cancer market is expected to grow at a CAGR of 7.9% during the forecast period. As per the World Health Organization, Asia Pacific is the second largest region in terms of new cases of prostate cancer globally. In 2018, around 321,000 new cases of prostate cancer were registered in the region. China has the highest incidence in the region followed by Japan however Australia has a very high incidence rate of prostate cancer. The highest rates of prostate cancer are reported in Australia and New Zealand presumably due to prostate-specific antigen (PSA) screening is done widely in these regions. In Asia Pacific, prostate cancer incidence has been reported to vary from country to country.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-prostate-cancer-diagnostic-therapeutic-market
There has been a consistent increase in the age-standardized incidence rates of prostate cancer in Asian countries over the last few decades, particularly in Singapore, China, Malaysia, and Japan. This has been reported to be due to changes in diet and other lifestyle factors in these countries. Moreover, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to provide a significant opportunity to the market.
Geographically, the market is divided into China, Japan, India and the Rest of Asia Pacific. China is expected to hold a major market share followed by Japan. Japan caters to a high geriatric population base due to which a significant market share to the region is anticipated during the forecast period. The companies which are contributing significantly in the market include Abbott Laboratories, AbbVie Products, LLC, Amgen Inc., Ferring Pharmaceuticals Inc., Johnson & Johnson, Siemens Healthcare AG, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
A full report of Asia Pacific Prostate Cancer Diagnostic and Therapeutic Market available @ https://www.omrglobal.com/industry-reports/asia-pacific-prostate-cancer-diagnostic-therapeutic-market
Asia Pacific Prostate Cancer Diagnostic and Therapeutic Market Segmentation
Asia Pacific Prostate Cancer Market by Diagnostic Techniques
- Prostate-Specific Antigen Test (PSA)
- Digital Rectal Examination
- Prostate Biopsy
- Imaging Techniques
Asia Pacific Prostate Cancer Market by Therapeutics
- Hormonal Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Targeted Therapy
- Surgery
Regional Analysis
- China
- Japan
- India
- Rest of Asia Pacific
Company Profiles
- Abbott Laboratories
- AbbVie Products, LLC
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Co.
- Endo Pharmaceuticals Inc.
- Ferring Pharmaceuticals Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Pfizer Inc.
- Siemens Healthcare AG
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research